BTIG Research has recently initiated Douglas Elliman Inc (DOUG) stock to Neutral rating, as announced on July 18, 2023, according to Finviz. Analyst ratings are significant because they provide ...
Shares of Aclaris Therapeutics (NASDAQ:ACRS) soared 60% Tuesday, the day after the company announced it was licensing two ...
BTIG analyst Marvin Fong raised the firm’s price target on RealReal (REAL) to $5.50 from $4 and keeps a Buy rating on the shares. The firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback